Bladder Cancer (BCa) Biochip
Why use Biochip?
Triaging patients with unexplained haematuria at primary care is a huge challenge with Bladder Cancer (BCa) being the 10th most common cancer worldwide, the 6th most common in men and 17th most common in women.
Cystoscopy is the active method for detecting BCa, despite being invasive and not without risk. Smaller tumours can be easily missed causing up to 30% of misdiagnosis and up to 50% incomplete TURBt (Trans Urethral Resection of Bladder Tumour). BCa tends to have a high recurrence rate therefore patients require lifetime monitoring.
Randox have demonstrated multiplex biomarkers approach is equal to the sensitivity and specificity of the gold standard cystoscopy.
The Evidence MultiSTAT
Meet the Evidence MultiSTAT
The Evidence MultiSTAT is an easy to use, small footprint analyser facilitating on-site simultaneous detection of multiple biomarkers.
Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results.
With minimal sample preparation required, this versatile benchtop analyser can achieve accurate, quantitative results in minutes.
Meet the Cartridge
The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.
The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error.
No other components are required.